KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBIT (2016 - 2025)

Historic EBIT for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $24.9 million.

  • Travere Therapeutics' EBIT rose 14440.15% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.1 million, marking a year-over-year increase of 7449.65%. This contributed to the annual value of -$323.8 million for FY2024, which is 1656.91% up from last year.
  • Travere Therapeutics' EBIT amounted to $24.9 million in Q3 2025, which was up 14440.15% from -$12.6 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' EBIT ranged from a high of $24.9 million in Q3 2025 and a low of -$139.2 million during Q1 2024
  • Moreover, its 5-year median value for EBIT was -$72.0 million (2022), whereas its average is -$66.4 million.
  • As far as peak fluctuations go, Travere Therapeutics' EBIT tumbled by 21558.37% in 2021, and later surged by 14440.15% in 2025.
  • Quarter analysis of 5 years shows Travere Therapeutics' EBIT stood at -$84.8 million in 2021, then fell by 2.18% to -$86.7 million in 2022, then fell by 8.69% to -$94.2 million in 2023, then skyrocketed by 35.55% to -$60.7 million in 2024, then surged by 141.05% to $24.9 million in 2025.
  • Its EBIT was $24.9 million in Q3 2025, compared to -$12.6 million in Q2 2025 and -$42.7 million in Q1 2025.